Replimune Group, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
REPL Nasdaq 2836 www.replimune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Replimune Group, Inc.

REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? - Aug 6th, 2026 3:37 pm
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen - Aug 6th, 2026 2:00 pm
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls - Aug 4th, 2026 7:37 am
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More - Aug 4th, 2026 6:11 am
Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval - Aug 4th, 2026 4:44 am
Why Did REPL, SNOW, NET Stocks Surge To 52-Week Highs Last Week? - Aug 2nd, 2026 9:17 pm
Why Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next - Aug 1st, 2026 10:14 pm
This Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatment - Jul 31st, 2026 2:22 pm
Top Midday Gainers - Jul 31st, 2026 11:39 am
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls - Jul 31st, 2026 7:46 am
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Jul 31st, 2026 4:45 am
Why Is REPL Stock Soaring 127% After Hours Today? - Jul 30th, 2026 6:14 pm
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma - Jul 30th, 2026 4:15 pm
REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug - Jul 28th, 2026 4:38 pm
Replimune Is Locked in a Standoff With Regulators. Here Is What It Means for the Stock. - Jul 28th, 2026 1:31 pm
Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy - Jul 28th, 2026 11:02 am
FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Jul 28th, 2026 8:55 am
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update - Jun 29th, 2026 6:00 am
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma - Jun 26th, 2026 6:00 am
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now - Jun 19th, 2026 6:24 am